Sisomicin: Bacteriological and clinical evaluation.
A preliminary study was conducted with sisomicin, a new aminoglycoside antibiotic. The drug was administered to 40 patients in doses varying from 1.5 to 3.75 mg/kg/day. Sisomicin proved to be an effective therapy in urinary tract infections and to a lesser extent in wound infections caused by gram-negative rods; favorable results have been observed in 91.6% and in 66.6% of the patients presenting these infections. Toxic reactions involving the hearing function, renal function, and general tolerance were infrequent: they occurred in less than 5% of the patients in this series. (However in approximately 22% of the patients, there was a transient appearance of granular casts in the urine.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008297:Male; D012853:Sisomicin / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D012853:Sisomicin